Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

NCT06958796

Status	RECRUITING
Phase	Phase 4
Sponsor	Camille N. Kotton, MD
Enrollment	80 participants

Key Eligibility Criteria

Inclusion (4)

- High risk pretransplant CMV donor seropositive/recipient seronegative (D+R-) kidney, liver, or simultaneous liver-kidney (SLK) transplant recipients
- Able to do routine blood testing (normal care for transplant recipients)
- Written informed consent obtained from the subject before any trial-related procedures
- Be e18 years and d75 years of age at time of consent

Exclusion (15)

- Any pre-transplant CMV serologic combinations besides CMV D+/R-
- Multi organ transplants (other than simultaneous liver-kidney transplant (SLK) recipients) or prior history of bone marrow or stem cell transplant
- Lung, heart, small bowel, pancreas, or other non-kidney or non-liver transplant recipients
- Transplant recipients treated for rejection within three months before the end of valganciclovir prophylaxis
- Participation in another interventional clinical trial at time of consent or within 30 days prior to study consent

... and 10 more (see full listing online)

Locations (2 total)

Massachusetts General Hospital, Boston, Massachusetts, United States
University of Texas Southwestern, Dallas, Texas, United States